Vitamin D5
| |
| Nazivi | |
|---|---|
| IUPAC naziv
(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(1R,4S)-4-etil-1,5-dimetilheksil]-7a-metil-2,3,3a,5,6,7-heksahidro-1H-inden-4-iliden]etiliden]-4-metilen-1-cikloheksanol
| |
| Identifikacija | |
3D model (Jmol)
|
|
| ChemSpider | |
| |
| Svojstva | |
| C29H48O | |
| Molarna masa | 412,69 |
Ukoliko nije drugačije napomenuto, podaci se odnose nastandardno stanjematerijala (na 25 °C [77 °F], 100 kPa). | |
 verifikuj(šta je  ?)
| |
| Reference infokutije | |
Vitamin D5je oblikvitamina D.
Analogna jedinjenja su predložena za upotrebu kao antitumorski agensi.[3][4][5]
Reference[уреди|уреди извор]
- ^Li Q, Cheng T, Wang Y, Bryant SH (2010).„PubChem as a public resource for drug discovery.”.Drug Discov Today.15(23-24): 1052—7.PMID20970519.doi:10.1016/j.drudis.2010.10.003.
- ^Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”.Annual Reports in Computational Chemistry.4:217—241.doi:10.1016/S1574-1400(08)00012-1.
- ^Mehta RG; Moriarty RM; Mehta RR; et al. (1997).„Prevention of preneoplastic mammary lesion development by a novel vitamin D analogue, 1alpha-hydroxyvitamin D5”.J. Natl. Cancer Inst.89(3): 212—8.PMID9017001.doi:10.1093/jnci/89.3.212.
- ^Murillo G, Mehta RG (2005).„Chemoprevention of chemically-induced mammary and colon carcinogenesis by 1alpha-hydroxyvitamin D5”.J. Steroid Biochem. Mol. Biol.97(1-2): 129—36.PMID16051482.doi:10.1016/j.jsbmb.2005.06.008.
- ^Mehta RG (2004).„Stage-specific inhibition of mammary carcinogenesis by 1alpha-hydroxyvitamin D5”.Eur. J. Cancer.40(15): 2331—7.PMID15454260.doi:10.1016/j.ejca.2004.05.025.
